PER-027-00
Completed
未知
Comparative, Double-blind, Randomized, Prospective, Multicenter Study to Evaluate the Local Tolerability of MK-0826 versus Sodium Ceftriaxone Administered by the Intramuscular Route.
MERCK SHARP & DOHME PERU S.R.L.,0 sites0 target enrollmentApril 18, 2000
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- MERCK SHARP & DOHME PERU S.R.L.,
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients\> 18 years of age with lower respiratory tract infection (ITRI), skin or soft tissue infection or urinary tract infection (UTI), as defined below, are suitable for inclusion. Both men and women are eligible.
- •Women of childbearing age whose urine pregnancy test is negative are eligible to enter the study; however, they must have a negative blood pregnancy confirmatory test (B\-HCG). The use of appropriate measures for birth control should be discussed with the investigator. Hormonal contraceptives should not be used as the sole method of birth control because the effect of MK\-0826 on the effectiveness of hormonal contraceptives has not yet been established. Breastfeeding women can participate if they agree to suspend breastfeeding for up to 5 days after the completion of therapy in order to allow the elimination of the drug from breast milk.
- •The patient´s infection should be severe enough to require I.M. therapy. and patients are expected to require a minimum of 2 doses (ie, 2 days) but no more than 7 doses of I.M. therapy.
- •At the investigator´s discretion, the patient´s infection is caused by microorganisms susceptible to the study antibiotics administered via I.M. See also the Criteria for Patients with ITRI (Infection of the Lower Respiratory Tract) which are found below for the case of subjects with possible atypical respiratory pathogens.
- •The patient´s infection has been treated using systemic antibiotic therapy for \<24 which is known to be effective against the presumed (s) pathogenic (s) pathogen (s) within a period of 72 days. hours immediately before entering the study. If the patient has received\> 24 hours of systemic antimicrobial therapy, there must be clear evidence that the patient did not respond to this regimen. Such evidence would include continued fever and persistence or worsening of symptoms related to the initial infection and / or laboratory changes or persistent radiographic or positive cultures.
- •Meets criteria for lower respiratory tract infection (community acquired pneumonia and acute exacerbation of chronic bronchitis) and skin infections.
Exclusion Criteria
- •1\) Does not meet all the inclusion criteria.
- •2\) History of coagulation problems or the patient is on anticoagulatory therapy.
- •3\) Patients who have received some intragluteal IM therapy in the previous 48 hours.
- •4\) Patients with some local pathology (for example: cellulitis, abscesses, ulcer) in the gluteal region.
- •5\) Infections known at the time of admission that are caused by pathogens resistant to any of the study drugs. This includes those patients who are at risk for anaerobic infections. Note: A macrolide can be added in case of suspicion of the existence of atypical respiratory pathogens.
- •6\) History of serious allergy, hypersensitivity (for example: anaphylaxis) or any adverse reaction to antibiotics of the family carbapenem (such as imipenem), ceftriaxone sodium or any cephalosporin or penicillin. Patients with a history of mild rash (not urticaria) to penicillins or other beta\-lactams can be enrolled.
- •7\) History of severe allergy, hypersensitivity, intolerance or any other adverse reaction to lidocaine or other similar local anesthetic agents. Also, patients with severe shock or heart block.
- •8\) Pregnant women, women who breastfeed or women of childbearing age who do not practice adequate methods of contraception; women who plan to get pregnant within the period of a month of the study. Those women who choose to stop breastfeeding for up to 5 days after the last dose of the study drug with the aim of allowing the elimination of the drug from breast milk will be eligible.
- •9\) Rapidly progressive or terminal disease, patients in whom a response to the antibiotic regimens described in this study or patients whose chances of surviving the study period are unlikely is considered unlikely.
- •10\) Patients who are hemodynamically unstable defined as: Limbs with poor perfusion, Pulse at rest\> 100 bpm and systolic pressure \<90 mm, Hg with the need for pressure or volume repletion,
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 2
Comparative study between Standard Dressing and Standard Dressing with Plant Extract of Jamelão in the treatment of Wounds on lower limbsRBR-9tqcr5qGilson Roberto de Araujo
Completed
Not Applicable
Hypertonic saline in cutaneous leishmaniasisCutaneous leishmaniasisSLCTR/2013/024Teaching Hospital Anuradhapura
Active, not recruiting
Not Applicable
Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study in order to assess the Safety, the behaviour of the investigational product in the human body and the Clinical Activity of I5NP to prevent Delayed Graft Function in Patients Undergoing Kidney Transplantation from deceased donorsEUCTR2010-020989-20-DEQuark Pharmaceuticals, Inc.326
Active, not recruiting
Not Applicable
Double-blind, double-dummy, randomised, comparative, multi-centre phase III study on the efficacy and tolerability of an 8-week oral treatment with 9 mg budesonide once daily vs. 3 mg budesonide three-times daily in patients with active Crohn’s disease - 9 mg budesonide OD vs. 3 mg budesonide TID in active Crohn’s diseaseEUCTR2008-006957-42-LVDr. Falk Pharma GmbH400
Active, not recruiting
Not Applicable
Double-blind, double-dummy, randomised, comparative, multi-centre phase III study on the efficacy and tolerability of an 8-week oral treatment with 9 mg budesonide once daily vs. 3 mg budesonide three-times daily in patients with active Crohn’s disease - 9 mg budesonide OD vs. 3 mg budesonide TID in active Crohn’s diseaseInduction of remission in active Crohn´s diseaseMedDRA version: 14.0Level: LLTClassification code 10058815Term: Crohn's disease acute episodeSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 14.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2008-006957-42-LTDr. Falk Pharma GmbH500